Biogen (BIIB) Tops Q1 EPS by 6c; cuts guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $250.69 -1.24%
EPS Growth %: -58.0%
Financial Fact:
Total revenues: 2.96B
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: -58.0%
Financial Fact:
Total revenues: 2.96B
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q1 EPS of $3.02, $0.06 better than the analyst estimate of $2.96. Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.23 billion.
GUIDANCE:
Biogen sees FY2025 EPS of $14.50-$15.50, versus the consensus of $15.20.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- FDA approves first once-weekly insulin for type 2 diabetes mellitus in pediatric patients
- AI-powered cyber threats light a fire under cybersecurity stocks
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
